| Relation: |
Strunz PP, Risser LM, Englbrecht M, Witte T, Froehlich M, Schmalzing M, Gernert M, Hueper S, Bartz-Bazzanella P, von der Decken C, Karberg K, Gauler G, Späthling-Mestekemper S, Kuhn C, Vorbrüggen W, Welcker M, Kleinert S. Use of Janus kinase inhibitors before and after European Medicines Agency safety recommendations: a retrospective study. Front Immunol. 2024 Aug 22;15:1445680. DOI:10.3389/fimmu.2024.1445680; Kleinert S, Bartz-Bazzanella P, von der Decken C, Knitza J, Witte T, Fekete SP, Konitzny M, Zink A, Gauler G, Wurth P, Aries P, Karberg K, Kuhn C, Schuch F, Späthling-Mestekemper S, Vorbrüggen W, Englbrecht M, Welcker M; RHADAR Group. A Real-World Rheumatology Registry and Research Consortium: The German RheumaDatenRhePort (RHADAR) Registry. J Med Internet Res. 2021 May 20;23(5):e28164. DOI:10.2196/28164; European Medicines Agency. EMA confirms measures to minimize risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. 11 Nov 2022 [zugegriffen am 8 Apr 2024]. Verfügbar unter: https://www.ema.europa.eu/en/news/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic-inflammatory-disorders#:~:text=EMA's%20human%20medicines%20committee%20(CHMP,treat%20several%20chronic%20inflammatory%20disorders; European Medicines Agency. Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (Upadacitinib) and Xeljanz (tofacitinb) — Updated recommendations to minimize the risks of malignancy, major adverse cardiovascular events, serious infections, venous thromboembolism and mortality with use of Janus kinase inhibitors (JAKi). 30 March 2023 [zugegriffen am 8 Apr 2024]. Available: https://www.ema.europa.eu/en/documents/dhpc/direct-healthcare-professional-communication-dhpc-updated-recommendations-minimise-risks-malignancy-major-adverse-cardiovascular-events-serious-infections-venous-thromboembolism-and-mortality-use_en.pdf; https://series.publisso.de/en/conferences/rhk2025/25rhk072; https://doi.org/10.3205/25rhk072 |